[{"NetIncomeLoss_1_Q2_USD":-79656000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":36685000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0_Q2_USD":34.17,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-21000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-6596000.0,"Depreciation_2_Q2_USD":4300000.0,"Depreciation_1_Q2_USD":2200000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q2_USD":82189000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2_Q2_USD":42.12,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":1173458.0,"StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1_Q2_USD":1000.0,"AssetsCurrent_0_Q2_USD":965618000.0,"OtherNoncashExpense_2_Q2_USD":889000.0,"FairValueNetAssetLiability_0_Q2_USD":16000000.0,"TreasuryStockShares_0_Q2_shares":195316.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":8210770.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":6345000.0,"TreasuryStockValue_0_Q2_USD":63000.0,"CommonStockSharesIssued_0_Q2_shares":62747821.0,"Assets_0_Q2_USD":1046532000.0,"ShareBasedCompensation_2_Q2_USD":29848000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":39297000.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":83021000.0,"CommonStockParOrStatedValuePerShare_0_Q2_CHF":0.03,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":-23595000.0,"CommonStockSharesAuthorized_0_Q2_shares":115172786.0,"CommitmentsAndContingencies_0_Q2_USD":null,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":201000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":61420746.0,"GeneralAndAdministrativeExpense_1_Q2_USD":21353000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":113573000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":59380000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0_Q2_USD":34.17,"AccountsReceivableNetCurrent_0_Q2_USD":33000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":756000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":379000.0,"CommonStockValue_0_Q2_USD":1900000.0,"OtherNonoperatingIncome_2_Q2_USD":5644000.0,"OtherNonoperatingIncome_1_Q2_USD":1412000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":13216000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":4283000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_Q2_shares":247493.0,"EffectiveIncomeTaxRateContinuingOperations_2_Q2_pure":-0.005,"EffectiveIncomeTaxRateContinuingOperations_1_Q2_pure":-0.005,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":90637000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-149415000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-79659000.0,"OtherAssetsNoncurrent_0_Q2_USD":662000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":945068000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":40317000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":1282952000.0,"Liabilities_0_Q2_USD":135862000.0,"RevenueFromRelatedParties_2_Q2_USD":318000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0_Q2_USD":27.23,"GeneralAndAdministrativeExpense_2_Q2_USD":40903000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":61134214.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":44000.0,"OperatingIncomeLoss_2_Q2_USD":-154275000.0,"OperatingIncomeLoss_1_Q2_USD":-80689000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0_Q2_shares":8197261.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":16302000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q2_USD":-3000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-148631000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-79277000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":15697000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":-28000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":-3000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-81454000.0,"LiabilitiesCurrent_0_Q2_USD":74505000.0,"AccountsPayableCurrent_0_Q2_USD":13219000.0,"NonoperatingIncomeExpense_2_Q2_USD":5644000.0,"NonoperatingIncomeExpense_1_Q2_USD":1412000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":20517000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_Q2_USD":-28000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":7616000.0,"CashAndCashEquivalentsFairValueDisclosure_0_Q2_USD":6784000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":1663000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":951371000.0,"StockIssuedDuringPeriodSharesStockOptionsExercised_2_Q2_shares":511141.0,"FiniteLivedIntangibleAssetsNet_0_Q2_USD":208000.0,"NumberOfOperatingSegments_2_Q2_Segment":1.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":2585000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":34444000.0,"NetIncomeLoss_2_Q2_USD":-149387000.0,"RestrictedCashNoncurrent_0_Q2_USD":6303000.0,"CommonStockSharesOutstanding_0_Q2_shares":62552505.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":-66000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":2559000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":759000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_Q2_USD":48.18,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_Q2_USD":18.78,"LiabilitiesAndStockholdersEquity_0_Q2_USD":1046532000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":10128000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":29848000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":15697000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0_Q2_USD":205800000.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":50746000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":9906000.0,"OperatingExpenses_2_Q2_USD":154476000.0,"OperatingExpenses_1_Q2_USD":80733000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":-201000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-2.44,"ProfitLoss_2_Q2_USD":-149387000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":9264000.0,"OtherLiabilitiesCurrent_0_Q2_USD":12429000.0,"StockholdersEquity_0_Q2_USD":910670000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q2_USD":11776000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":6596000.0,"IncreaseDecreaseInOtherOperatingLiabilities_2_Q2_USD":-3652000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q2_shares":8197261.0,"TaxesPayableCurrent_0_Q2_USD":1507000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0_Q2_shares":3745480.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-374098000.0,"PropertyPlantAndEquipmentFairValueDisclosure_0_Q2_USD":9340000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-1.3,"AccruedProfessionalFeesCurrent_0_Q2_USD":1742000.0,"Ticker":"CRSP","CIK":"1674416","name":"CRISPR THERAPEUTICS AG","OfficialName":"CRISPR Therapeutics AG Common Shares","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"4543904930.0","Country":"Switzerland","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20200727"}]